Among calcineurin inhibitors (CNIs), cyclosporine has a greater impact on metabolic and cardiovascular comorbidities than tacrolimus [9, 17–19], while the mammalian target of rapamycin (mTOR) inhibitors lower the risk of metabolic syndrome compared to CNIs, except for their impact on fat metabolism [20]. The gene discussed is MTOR; the disease is metabolic syndrome.